🇺🇸 FDA
Patent

US 9364448

Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation

granted A61KA61K31/122A61K8/35

Quick answer

US patent 9364448 (Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/122, A61K8/35, A61K8/40, A61P